Pipeline

Pipeline


Product / Indication Pre Clinical Phase 1 Phase 2 Phase 3 NDA Review
Fostamatinib - ITP
Indication: Immune Thrombocytopenia
Target: SYK
  • 90%
Fostamatinib - AIHA
Indication: Autoimmune Hemolytic Anemia
Target: SYK
  • 50%
Fostamatinib - IgAN
Indication: IgA Nephropathy
Target: SYK
  • 50%
BGB324 - Oral Axl Inhibitor
Indication: Cancer
Partner: BerGenBio
  • 42%
DS-3032 - MDM2 Inhibitor
Indication: Cancer
Partner: Daiichi Sankyo
  • 37%
ATI-50001 & 50002 - JAK Inhibitors
Indication: Dermatology
Partner: Aclaris
  • 30%
TGF-beta Inhibitors
Indication: Cancer/Immunotherapy
Partner: Bristol-Myers Squibb
  • 18%
AZD0449 - Inhaled JAK Inhibitor
Indication: Chronic Asthma
Partner: AstraZeneca
  • 15%
Partner-sponsored Trials
Company-sponsored Trials